Benzinga | Dec 21, 2021 08:14AM EST

Hepion Pharmaceuticals Announces FDA Clearance Of IND Application For CRV431 In The Treatment Of Liver Cancer

- New IND Expands Liver Disease Pipeline for CRV431 -

- IND Clearance Allows CRV431 to Move Directly into Phase 2 for Hepatocellular Carcinoma Treatment -

- New IND Provides for Complementary Therapeutic Approach of Treating NASH and Liver Cancer with a Single Once-a-Day Oral Agent -